Hong Kong News
Nonpartisan, Noncommercial, unconstrained.
Friday, Apr 26, 2024
Real, Diverse, Unbiased.
Woman in New Zealand dies from heart inflammation following Pfizer jab
The woman developed myocarditis — a known, rare side effect of mRNA COVID-19 vaccination.
The Pfizer/BioNTech vaccine is believed to be partly responsible for the death of a woman in New Zealand, authorities said on Monday.
New Zealand's Ministry of Health said that the woman's death was due to myocarditis — an inflammation of the heart muscle which can reduce the heart's ability to pump — developed after she had been administered the Pfizer vaccine, also known as Comirnaty.
Myocarditis is a known, rare effect of mRNA COVID-19 vaccination.
"The case has been referred to the Coroner and the cause of death has not yet been determined," the ministry said.
"The CV-ISMB (COVID-19 Independent Safety Monitoring Board) considered that the myocarditis was probably due to vaccination. The CV-ISMB noted that there were other medical issues occurring at the same time which may have influenced the outcome following vaccination," it added.
The Ministry stressed however that "the benefits of vaccination after the Pfizer COVID-19 vaccine continue to greatly outweigh the risk of both COVID-19 infection and vaccine side effects".
The European Medicines Agency (EMA) listed myocarditis and pericarditis — another inflammatory condition of the heart — as possible side effects of COVID-19 vaccination on July 9.
The listing was based on an in-depth review of 145 cases of myocarditis in the European Economic Area (EEA) among people who had received Comirnaty and 19 cases among people who received Spikevax, developed by Moderna. The EMA's safety committee also reviewed 138 cases of pericarditis following Comirnaty injections and 19 cases following the use of Spikevax.
It noted that during the assessment period, around 177 million doses of Comirnaty and 20 million doses of Spikevax had been administered in the EEA's 31 countries.
It concluded that the cases primarily occurred within 14 days after vaccination, more often after the second dose, and that it primarily affected younger adult men.
"In five cases that occurred in the EEA, people died. They were either of advanced age or had concomitant diseases," it said.
"Available data suggest that the course of myocarditis and pericarditis following vaccination is similar to the typical course of these conditions, usually improving with rest or treatment," it went on.
The US Centers for Disease Control and Prevention (CDC) said it had received more than 1,000 reports of cases of inflammation of the heart after mRNA COVID-19 vaccination between April and late June.
"These reports were rare, given the hundreds of millions of vaccine doses administered," it said.
Both public health agencies continue to recommend vaccination.
New Zealand's Ministry of Health said that the woman's death was due to myocarditis — an inflammation of the heart muscle which can reduce the heart's ability to pump — developed after she had been administered the Pfizer vaccine, also known as Comirnaty.
Myocarditis is a known, rare effect of mRNA COVID-19 vaccination.
"The case has been referred to the Coroner and the cause of death has not yet been determined," the ministry said.
"The CV-ISMB (COVID-19 Independent Safety Monitoring Board) considered that the myocarditis was probably due to vaccination. The CV-ISMB noted that there were other medical issues occurring at the same time which may have influenced the outcome following vaccination," it added.
The Ministry stressed however that "the benefits of vaccination after the Pfizer COVID-19 vaccine continue to greatly outweigh the risk of both COVID-19 infection and vaccine side effects".
The European Medicines Agency (EMA) listed myocarditis and pericarditis — another inflammatory condition of the heart — as possible side effects of COVID-19 vaccination on July 9.
The listing was based on an in-depth review of 145 cases of myocarditis in the European Economic Area (EEA) among people who had received Comirnaty and 19 cases among people who received Spikevax, developed by Moderna. The EMA's safety committee also reviewed 138 cases of pericarditis following Comirnaty injections and 19 cases following the use of Spikevax.
It noted that during the assessment period, around 177 million doses of Comirnaty and 20 million doses of Spikevax had been administered in the EEA's 31 countries.
It concluded that the cases primarily occurred within 14 days after vaccination, more often after the second dose, and that it primarily affected younger adult men.
"In five cases that occurred in the EEA, people died. They were either of advanced age or had concomitant diseases," it said.
"Available data suggest that the course of myocarditis and pericarditis following vaccination is similar to the typical course of these conditions, usually improving with rest or treatment," it went on.
The US Centers for Disease Control and Prevention (CDC) said it had received more than 1,000 reports of cases of inflammation of the heart after mRNA COVID-19 vaccination between April and late June.
"These reports were rare, given the hundreds of millions of vaccine doses administered," it said.
Both public health agencies continue to recommend vaccination.
